ALCIDION GROUP LIMITED (ALC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALC

ALC - ALCIDION GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: N/A
Index:

Alcidion Group provides clinical information technology to support clinicians in decision making, ensuring quality of care for patients. The company operates in Australia and the UK. It listed on the ASX in 2011.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.097

07 Oct
2025

0.004

OPEN

$0.09

4.30%

HIGH

$0.10

331,290

LOW

$0.09

TARGET
$0.13 34.0% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . BMT . DOC . EBO . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
ALC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 0.1 - 0.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx40.8 M
Book Value Per Share xxxxxxxxxxxxxxx-
Net Operating Cash Flow xxxxxxxxxxxxxxx-
Net Profit Margin xxxxxxxxxxxxxxx4.06 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-
Return on Assets xxxxxxxxxxxxxxx-
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx-
Long Term Debt xxxxxxxxxxxxxxx-
Total Debt xxxxxxxxxxxxxxx-
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx-
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx-
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx-
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

29/08/2025

1

Upgrade to Buy from Hold

$0.13

34.02%

Alcidion Group's FY25 revenue of $40.8m rose 10% year-on-year, in line with Bell Potter's forecasts, driven by the $8.4m upfront licence fee from the National Crime Information Center (NCIC) contract.

Earnings (EBITDA) of $4.8m delivered a $9.4m turnaround from FY24, beating both guidance (of above $4.5m) and the broker’s $4.7m forecast, supported by higher margins and a $0.9m currency benefit.

The group ended June with $17.7m cash and no debt, delivering its maiden profit on the back of the NCIC hospital contract, explain the analysts.

FY26 guidance includes being earnings and operating cash flow positive in FY26 and recognition of $140m contracted revenue through to 2030.

The broker makes modest forecast reductions, raising forecasts for operating expenses and depreciation. The target price remains unchanged at 13c. Bell Potter upgrades to a Buy rating from Hold.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.70 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

27/04/2025

1

Buy

$0.13

34.02%

Alcidion Group's 3Q25 update showed contracted revenue rose to $40.2m from $39.5m in February, prompting Canaccord Genuity to slightly upgrade revenue and earnings (EBITDA) estimates for FY25.

The broker notes the company's fixed cost base has opened up the opportunity for operating leverage in FY26 and beyond.

EPS estimates largely unchanged. Buy. No change to 13c target.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.10 cents.
Access Extra Coverage Research History >

ALC STOCK CHART

FNArena News on ALC

1
Weekly Ratings, Targets, Forecast Changes – 29-08-25

Sep 01 2025 - Weekly Reports
2
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia
3
Weekly Ratings, Targets, Forecast Changes – 25-07-25

Jul 28 2025 - Weekly Reports
4
Rudi’s View: Extreme Bifurcation Ahead Of August

Jul 23 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Apr 27, 2025

Apr 28 2025 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps